Aptus Pharma Ltd vs Fabino Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Aptus Pharma Ltd is ₹ 405 as of 30 Apr 15:30 . The P/E Ratio of Aptus Pharma Ltd is 0 as of March 2023 .The P/E Ratio of Fabino Enterprises Ltd is 600 as of March 2023 . The Market Cap of Aptus Pharma Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Fabino Enterprises Ltd is ₹ 6.3 crore as of March 2023 . The Dividend Payout of Aptus Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aptus Pharma Ltd

Aptus Pharma Limited was originally incorporated as 'Aptus Pharma Private Limited', as a private limited company with the Registrar of Companies, Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010.
Subsequently, Company was converted into a public limited retaining the name as 'Aptus Pharma Limited' and a fresh certificate of incorporation dated December 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations.
While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model with 7 units. under various arrangements.
It provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products.

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

FAQs for the comparison of Aptus Pharma Ltd and Fabino Enterprises Ltd

Which company has a larger market capitalization, Aptus Pharma Ltd or Fabino Enterprises Ltd?

Market cap of Aptus Pharma Ltd is 277 Cr while Market cap of Fabino Enterprises Ltd is 4 Cr

What are the key factors driving the stock performance of Aptus Pharma Ltd and Fabino Enterprises Ltd?

The stock performance of Aptus Pharma Ltd and Fabino Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aptus Pharma Ltd and Fabino Enterprises Ltd?

As of May 4, 2026, the Aptus Pharma Ltd stock price is INR ₹405.0. On the other hand, Fabino Enterprises Ltd stock price is INR ₹20.31.

How do dividend payouts of Aptus Pharma Ltd and Fabino Enterprises Ltd compare?

To compare the dividend payouts of Aptus Pharma Ltd and Fabino Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.